Global Longlife Hospital and Research Limited

Global Longlife Hospital and Research Limited

BBSE:GLHRL
12.68
INR
+0.58
(+4.79%)
143.43MMarket Cap
Global Longlife Hospital and Research Limited
BSE:GLHRL
(Bombay Stock Exchange)

Recent

price

12.68

P/E

ratio

- -

div

yld

- -

ROIC.AI

2019
2020
2021
2022
2023
2024
2025
2026
TTM
INR
32.9
31.95
31.15
31.25
23.08
12.87
0.55
- -
- -
Revenue per Share
1.3
-0.82
1.95
3.4
1.79
-2.08
0.19
-1.64
- -
Basic EPS, GAAP
4.76
3.61
6.51
8.52
-41.65
-5.83
11.71
-4.29
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
11.76
10.94
13.03
16.15
61.23
24.7
25.51
22.62
22.62
Book Value per Share
11.74
10.94
13.02
16.15
61.22
24.68
25.51
22.62
22.62
Tangible Book Value per Share
11
11
11
11
10
11
10
11
11
Basic Weighted Avg Shares
345
335
327
328
235
135
6
- -
- -
Sales/Revenue/Turnover
15.06
5.48
14.39
21.79
12.34
-11.07
-803.86
- -
- -
Operating Margin (%)
22
21
13
11
12
13
5
- -
- -
Depreciation Expense
14
-9
20
36
18
-22
2
-17
- -
Net Income, GAAP
49.22
- -
- -
37.41
32.51
- -
- -
- -
- -
Effective Tax Rate (%)
3.95
-2.57
6.26
10.89
7.78
-16.19
34.42
- -
- -
Profit Margin (%)
22
24
15
-24
257
-84
226
203
203
Working Capital
177
169
125
28
36
34
- -
- -
- -
LT Debt
124
115
137
170
643
259
268
237
237
Total Equity
- -
- -
- -
15.23
3.99
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
16.03
4.12
- -
- -
- -
- -
Return on Capital (%)
- -
-7.23
16.27
23.33
4.5
-4.85
0.75
-6.8
- -
Return on Common Equity (%)

Capital Structure

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
11
11
Market Capitalization
199
267
143

Working Capital

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
226
217
203
Cash, Cash Equivalents & STI
215
211
170
Accounts Receivable, Net
3
3
2
Inventories
- -
- -
- -
Total Current Liabilities
1
- -
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
47.07%
-11.35%
Free Cash Flow
- -
-213.11%
-136.82%
Net Income, GAAP
- -
-253.69%
-965.37%
Sales/Revenue/Turnover
- -
-53.25%
-100%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
135
2025
- -
- -
6
2026
- -
- -
- -

Semi-annual Earnings Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-2.08
2025
- -
- -
0.19
2026
- -
- -
-1.64

Semi-annual Dividends Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -
Business
Global Longlife Hospital and Research Limited (GLHRL.BO) operates as a multi-specialty healthcare provider in India, offering a comprehensive range of medical services including cardiology, neurology, orthopedics, oncology, gastroenterology, nephrology, and critical care; diagnostic services such as imaging, pathology, and laboratory testing; and advanced treatments like organ transplants, robotic surgery, and intensive care units. The company manages hospitals equipped with state-of-the-art facilities, providing inpatient, outpatient, and day-care services to patients across diverse demographics, with a focus on tertiary and quaternary care in urban and semi-urban markets. Founded in 1990 and headquartered in Chennai, India, it primarily serves patients in southern India through its network of facilities, with expansion into other regions via strategic hospital developments. In recent developments within the last two years, Global Longlife Hospital and Research Limited has pursued business expansions by inaugurating new specialty centers and upgrading existing infrastructure to enhance capacity for high-acuity procedures; formed partnerships with international medical device manufacturers for advanced equipment adoption; and secured funding through equity offerings to support digital health initiatives like telemedicine platforms. The company has also launched new service offerings in precision medicine and genomic testing, alongside strategic alliances with pharmaceutical firms for clinical trials. These changes reflect a shift toward integrated healthcare ecosystems, including outpatient clinics and wellness programs, amid growing demand in India's private healthcare sector.